The Neuroprotection Research Stack: Cerebrolysin, Semax, Selank, and NAD+

Neuroprotection as a research category encompasses both acute and chronic timescales. Acute neuroprotection — limiting damage following stroke, traumatic brain injury, or excitotoxic event — requires rapid intervention that reduces neuronal death in the hours to days following insult. Chronic neuroprotection — slowing the progressive neuronal loss associated with aging, neurodegeneration, and chronic stress — operates on a fundamentally different timescale and requires sustained biological support.

Excitotoxicity (the mechanism by which excessive glutamate receptor activation floods neurons with calcium, triggering apoptotic and necrotic cell death cascades; responsible for the neuronal death that extends beyond the immediate injury zone in stroke and TBI) and oxidative stress (the cumulative damage produced when reactive oxygen species exceed the cell's antioxidant capacity; neurons are particularly vulnerable due to their high metabolic rate and limited intrinsic antioxidant defenses) represent the two primary acute mechanisms that neuroprotective research targets.

Chronic neuroprotection research focuses on neurotrophic factor decline (the progressive reduction in BDNF, NGF, GDNF, and related survival signals that occurs with aging and stress), neuroinflammation (chronic microglial activation producing a pro-inflammatory CNS environment that progressively damages neurons), and mitochondrial dysfunction (progressive impairment of neuronal energy production that impairs synaptic function and ultimately cell survival). A layered research protocol can address all three chronic mechanisms simultaneously.

Cerebrolysin (a standardized mixture of low molecular weight neuropeptides and free amino acids derived from porcine brain protein by controlled enzymatic hydrolysis; contains approximately 25% low molecular weight peptides (below 10 kDa) and 75% free amino acids; the active peptide fraction includes fragments of BDNF, NGF, GDNF, and CNTF) provides something that synthetic peptides cannot: a mixture of neurotrophic peptide fragments that collectively engage multiple trophic receptor pathways simultaneously.

The evidence base for Cerebrolysin is uniquely clinical. Published RCTs in Alzheimer's disease (using ADAS-cog primary endpoints), MCI, vascular dementia, and stroke recovery provide a level of human interventional data that most neuroprotective compounds lack. The Austrian and Russian clinical registration programs have generated a substantial body of evidence that, while debated in terms of statistical robustness, represents the largest published clinical dataset for any neuropeptide mixture in neurological disease.

The proposed mechanism relevant to chronic neuroprotection is multifactorial: Cerebrolysin peptide fragments provide direct trophic support to neurons (stimulating TrkB and p75NTR receptors), reduce amyloid precursor protein processing toward the amyloidogenic pathway, modulate tau phosphorylation through GSK-3beta inhibition, and suppress neuroinflammatory microglial activation through IL-6 and TNF-alpha pathway modulation. This breadth of mechanism is a research advantage for studying complex neurodegenerative processes but a challenge for isolating specific mechanistic contributions.

Semax (the heptapeptide ACTH(4-7)PGP — a synthetic analog of the 4 through 7 fragment of adrenocorticotropic hormone modified with a C-terminal proline-glycine-proline extension that significantly extends its plasma stability; registered in Russia for stroke, TBI, and optic nerve disease; studied primarily for its ability to upregulate BDNF (brain-derived neurotrophic factor — the most widely studied neurotrophin; critical for long-term potentiation (the synaptic strengthening mechanism underlying memory formation), dendritic branching, neuronal survival under stress, and adult hippocampal neurogenesis) in CNS tissue) addresses the trophic factor layer with more mechanistic specificity than Cerebrolysin.

Published Russian clinical studies have measured BDNF elevation in human CSF and blood following Semax administration, establishing that the compound's BDNF-upregulating effect — robustly demonstrated in rodent models — extends to human subjects. This makes Semax one of very few compounds with both preclinical mechanistic data for BDNF upregulation and human biomarker data confirming the same effect.

The ACTH origin of Semax's structure is relevant to its mechanism: ACTH fragments interact with melanocortin receptors in the brain (MC4R in particular), and these receptors are expressed in neurons, astrocytes, and microglia. MC4R activation in neurons promotes BDNF expression through cAMP-PKA-CREB signaling — the same downstream pathway activated by antidepressants and exercise-induced BDNF elevation. This positions Semax as a melanocortin receptor-mediated BDNF upregulator, with a mechanism that overlaps with both antidepressant biology and exercise neurobiology.

Selank (the heptapeptide tuftsin analog Thr-Lys-Pro-Arg-Pro-Gly-Pro — a synthetic modification of tuftsin, an endogenous immunomodulatory tetrapeptide; registered in Russia as an anxiolytic; studied for modulation of the HPA axis, GABA-A receptor function, and BDNF expression; notable for a clinical anxiolytic effect without the sedation or dependence associated with benzodiazepines) addresses a layer that neither Cerebrolysin nor Semax covers comprehensively: chronic stress-mediated neuropathology.

Glucocorticoids (the stress hormones, primarily cortisol in humans and corticosterone in rodents; secreted by the adrenal cortex in response to HPA axis activation; have both essential adaptive effects at normal levels and documented neurotoxic effects at chronically elevated levels — particularly suppression of hippocampal neurogenesis, reduction of BDNF expression, and acceleration of hippocampal volume loss) represent one of the most important drivers of stress-related neurological damage. Chronic HPA axis hyperactivation produces sustained glucocorticoid exposure that progressively impairs the hippocampus — the brain region most critical for memory formation and most sensitive to glucocorticoid excess.

Selank's published mechanism includes HPA axis normalization — reducing excessive corticosterone levels in stressed rodent models — and modulation of GABA-A receptor sensitivity in a benzodiazepine-like manner without direct benzodiazepine site binding. In a neuroprotection research context, Selank's stress axis modulation complements Semax's BDNF upregulation: Semax stimulates BDNF production, but chronic glucocorticoid excess actively suppresses BDNF expression. Reducing that glucocorticoid suppression through Selank's HPA axis modulation removes the counteracting signal that would otherwise limit Semax's BDNF-upregulating effect.

Neurons have the highest energy demand of any cell type in the body relative to their size. A single pyramidal neuron can have up to 10,000 synaptic connections, each requiring ATP for vesicle loading, membrane potential maintenance, and signal transduction. This extraordinary energy demand makes neurons uniquely sensitive to mitochondrial dysfunction — a 20% reduction in mitochondrial efficiency that might be well tolerated in muscle or fat tissue can produce clinically significant synaptic failure and neuronal stress in neurons.

The age-related NAD+ decline documented in peripheral tissues has also been shown in brain tissue. Published rodent studies have demonstrated that brain NAD+ levels decline with aging and that this decline is associated with reduced sirtuin activity (particularly SIRT1 and SIRT3 in neurons), increased neuroinflammation, impaired DNA repair, and accelerated features of neurodegeneration in genetic models. NAD+ restoration in aged rodents partially reverses these neurological aging phenotypes.

For the neuroprotection research stack, NAD+'s neuronal energy restoration role is complementary to the trophic factor support and stress axis modulation provided by the other layers. Trophic signals like BDNF require energy to act on neurons: the synaptic strengthening, dendritic branching, and survival pathway activation driven by BDNF are all energetically expensive. Without adequate neuronal mitochondrial function, neurons may lack the metabolic capacity to respond effectively to trophic support. NAD+ restores the metabolic floor on which the other neuroprotective signals operate.

The four-layer neuroprotection framework produces interactions that are not simply additive. Each layer addresses a different aspect of the neurological vulnerability profile, and some layers facilitate the effectiveness of others.

Cerebrolysin and Semax operate on related but distinct trophic mechanisms: Cerebrolysin provides exogenous peptide fragments that directly stimulate trophic receptors (TrkB, p75NTR), while Semax upregulates endogenous BDNF production. Together they engage both the supply side (Semax: make more BDNF) and the receptor side (Cerebrolysin: directly activate trophic receptors) of neuronal survival signaling. Published combination research in stroke models has suggested that trophic factor stimulation and direct receptor activation may produce complementary rather than redundant effects.

Selank's stress axis modulation enhances the effectiveness of Semax's BDNF upregulation, as described above. But Selank also reduces neuroinflammation independently of its HPA axis effects: published studies have shown reduced IL-6 and TNF-alpha in CNS tissue following Selank administration, creating a less hostile inflammatory environment for the trophic support that Cerebrolysin and Semax provide.

NAD+'s neuronal energy restoration underpins the entire stack by ensuring neurons have the metabolic capacity to respond to the trophic signals, plasticity signals, and stress reduction provided by the other compounds. The order of dependency is: NAD+ (energy floor) → Selank (stress reduction allowing trophic signal reception) → Cerebrolysin and Semax (trophic signals and BDNF elevation).

Neuroprotection research protocol design requires decisions that are more complex than most other research categories because the brain is uniquely difficult to measure non-invasively and uniquely sensitive to confounding variables.

For Cerebrolysin, published clinical trials used IV administration in 10-20 day courses at 10-30 mL per day. This protocol reflects the pharmacokinetics: Cerebrolysin's low molecular weight peptide fractions are rapidly cleared, requiring sustained administration to maintain tissue levels sufficient for trophic effect. The course length reflects the time required for neuronal structural remodeling in response to trophic signaling — a process that occurs over days to weeks, not hours.

For Semax, intranasal administration has been used in most published studies and clinical applications. Nasal administration bypasses the blood-brain barrier via olfactory nerve transport, achieving CNS penetration without systemic injection. The intranasal route has been validated in human subjects through CSF BDNF measurement following nasal Semax administration.

For Selank, intranasal administration similarly bypasses the blood-brain barrier and is the primary route used in published Russian clinical research. Timing relative to stress exposure matters: published anxiolytic studies show best results with administration before or during stress exposure rather than retrospectively.

For NAD+, the neurological research context favors routes that achieve rapid CNS NAD+ restoration: IV administration achieves the fastest systemic NAD+ elevation, but oral NMN is suitable for longer protocols where the goal is sustained NAD+ maintenance rather than acute restoration.

Researchers studying neuroprotection, neurotrophic factor biology, and CNS aging can review Cerebrolysin, Semax, Selank, and NAD+ product specifications at Blackwell BioLabs. All batches are verified by third party testing with HPLC purity confirmation and mass spectrometry identity verification on every lot.